Latest Advances in Gene & Cell Therapy Development Presented at ESGCT2024
31st Annual Congress of the European Society of Gene & Cell Therapy
Researchers from iBET’s Cell Line Development and Molecular Virology and the Stem and Immune Cells Bioengineering Laboratories recently participated in the 31st Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), held in Rome, Italy, from October 22-25.
This event brought together global experts in the field to collaborate, showcase and discuss the latest advancements in Gene Therapy, Cell Therapy and Genetic Vaccines.
iBET’s team presented 4 posters detailing their latest work in the following topics:
- Ana Sofia Coroadinha (Head of Cell Line Development and Molecular Virology Lab) – “Genetically encoded sensor circuits for the development of therapies for infectious diseases: a theragnostic approach”
- Sofia Fernandes – “Improving rAAV production: key adenoviral elements and their impact on vector yield and quality”
- Hélio Tomás – “Production of lentiviral vectors for the generation of Car-T Cells in an integrated manufacturing process in stirred-tank bioreactors”
- Rodrigo Nogueira – “Assessing the potential of a mutated HIV-1 protease for continuous stable lentiviral vector production”
Moreover, other scientists from iBET, including Ximena Garate and Vanessa Bandeira, also attended the conference.
Founded in 1992, ESGCT seeks to promote basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe. This year’s edition was co-organized with the Italian Society for Gene and Cell Therapies.